This is a transformative reverse merger that hands control of the public shell to North Immunology's shareholders and provides at least $150M in fresh capital. Existing AEMD shareholders face massive dilution — the 477K pre-deal shares will represent a tiny fraction of the post-merger company. The PIPE at a minimum of $150M signals strong institutional backing for North Immunology's pipeline. Monitor the S-4 registration statement for detailed pro-forma ownership and the stockholder vote timeline. The deal has a June 17, 2027 outside date.
Price Chart
Executive Summary
Aethlon Medical (AEMD) entered into a definitive merger agreement to acquire North Immunology, Inc. in a reverse-merger transaction structured as a tax-free reorganization. Aethlon will issue shares of its common stock to North Immunology stockholders based on a formula valuing North Immunology at $150 million and Aethlon at $16.5 million (subject to net cash adjustments). Concurrently, North Immunology is raising at least $150 million (minimum $175 million) in a PIPE financing from institutional investors, which will close substantially concurrently with the merger. The combined entity will operate as 'North Immunology, Inc.' and continue trading on Nasdaq. This is a transformative reverse merger that effectively hands control of the public shell to North Immunology's shareholders and provides the combined company with significant cash runway.
Key Financial Metrics
Key Facts
- Aethlon Medical (AEMD) to acquire North Immunology, Inc. via reverse merger structured as a tax-free reorganization under Section 368(a) of the Code
- North Immunology valued at $150 million (Company Equity Value); Aethlon valued at $16.5 million (Parent Valuation), subject to net cash adjustments
- North Immunology stockholders to receive shares of Aethlon common stock based on an Exchange Ratio formula; Aethlon will change its name to 'North Immunology, Inc.'
- Concurrent PIPE financing of at least $150 million (minimum $175 million) from institutional investors, closing substantially concurrently with the merger
- Aethlon had only 477,402 shares outstanding as of June 30, 2026, with a market cap of approximately $2 million — the merger represents a massive dilution for existing Aethlon shareholders
- Existing Aethlon CEO/CFO employment agreements were amended 2 days prior to convert severance to lump sums upon change in control — consistent with a planned transaction
- Aethlon will wind down its legacy business and terminate its R&D activities; proceeds from any legacy asset sales will be distributed to CVR holders
- The combined company will be led by North Immunology's management team and board
Financial Impact
North Immunology valued at $150M equity value; PIPE financing of at least $150M (minimum $175M); Aethlon valued at $16.5M subject to net cash adjustments
Risk Factors
- Massive dilution for existing AEMD shareholders — the 477K pre-deal shares will be a very small percentage of the combined company
- Transaction requires approval from both Aethlon and North Immunology stockholders; Aethlon's small shareholder base may be concentrated
- PIPE financing of at least $150M is a condition to closing — if the PIPE fails, the deal terminates
- Integration risk: Aethlon is a clinical-stage medical device company, while North Immunology is a biotech — different business models
- Aethlon's legacy business wind-down and asset sales may create distractions and potential liabilities
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001683168-26-007206 |
| Document: aethlon_ex1004.htm | 0001683168-26-007206 |
| Document: aethlon_ex1005.htm | 0001683168-26-007206 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | SC 13G | $5.05 $5.07 | ▲ +0.40% | ▼ −0.06% | $5.07 (+0.40%) |
Oct 1, 2026 26d ago | 8-K | $6.45 $6.05 | ▲ +6.20% | ▲ +7.36% | $5.07 (+21.40%) |
Sep 17, 2026 5w ago | 425 | $6.78 $6.77 | ▼ −0.15% | ▼ −0.75% | $5.07 (−25.22%) |
Sep 17, 2026 5w ago | 8-K | $6.78 $6.77 | ▼ −0.15% | ▼ −0.75% | $5.07 (−25.22%) |
Sep 15, 2026 6w ago | 8-K | $1.47 $6.31 | ▲ +329.25% | ▲ +328.43% | $5.07 (+244.90%) |
Sep 4, 2026 7w ago | DEFA14A | $1.81 $1.47 | ▲ +18.78% | ▲ +17.67% | $5.07 (−180.11%) |
Aug 31, 2026 8w ago | 8-K | $2.06 $1.81 | ▼ −12.14% | ▼ −11.99% | $5.07 (+146.12%) |
Aug 13, 2026 10w ago | Press Release | $2.83 $2.73 | ▼ −3.53% | ▼ −2.17% | $5.07 (+79.15%) |
Jul 31, 2026 12w ago | 8-K | $0.6628 $0.6300 | ▲ +4.95% | ▲ +8.46% | $5.07 (−664.94%) |
Jul 7, 2026 16w ago | EFFECT | $0.7297 $0.6850 | ▲ +6.13% | ▲ +6.68% | $5.07 (−594.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers